Protalix BioTherapeutics Discloses Three New Compounds in Development

Protalix BioTherapeutics Discloses Three New Compounds in Development

                 - Oral PRX-106 for immune mediated disorders
                      - PRX-110 for Cystic Fibrosis (CF)
   - PRX-107 for emphysema due to hereditary alpha1-antitrypsin deficiency

CARMIEL, Israel, June 20, 2013 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics,
Inc. (NYSE:PLX) (TASE:PLX), today held an Analyst Event in which included the
disclosure of new data regarding three new compounds in development, oral
PRX-106 for immune mediated disorders, PRX-110 for Cystic Fibrosis (CF), and
PRX-107 for emphysema from heredity alpha1-antitrypsin (AAT) deficiency.

"Our validated plant-cell based platform, ProCellEx®, has the capacity to
generate a diverse array of protein therapeutics, each with highly unique
characteristics. With this next wave of compounds and oral administration
modalities, we are building a strong pipeline and potentially treatment
advances to patients," said Dr. David Aviezer, Protalix BioTherapeutics'
President and Chief Executive Officer.

PRX-106 is the Company's proprietary plant cell recombinant Anti-TNF fusion
protein being developed as an orally-administered treatment for immune
mediated disorders. In preclinical studies, oral PRX-106 alleviated
immune-mediated hepatitis and reduced interferon gamma levels in a
concanavalin A (ConA) mouse model. Additionally, oral administration of
PRX-106 alleviated immune mediated colitis, a well established model for
Crohn's disease, promoting serum levels of anti-inflammatory IL-10 and
regulatory T-cells.The Company is conducting additional preclinical studies
for oral PRX-106 in additional attractive indications.

PRX-110 is the Company's proprietary plant cell recombinant human
Deoxyribonuclease 1 (DNase 1) under development for the treatment of CF, to be
administered by inhalation.PRX-110 works by cleaving extracellular DNA and
thinning the thick mucus that accumulates in CF patients' lungs.In
preclinical trials, PRX-110 demonstrated improved enzyme kinetics, less
sensitivity to inhibition by actin and improved ex-vivo efficacy when compared
to Pulmozyme®, the only approved form of recombinant DNase 1 manufactured in
Chinese hamster ovary (CHO) cells.The Company held a pre-Investigational New
Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) in 2012,
and plans to file an IND with the FDA following the completion of toxicology
studies, which is expected to occur by year end.

PRX-107 is the Company's proprietary plant cell recombinant human
Alpha1-antitrypsin (AAT) under development for the treatment of emphysema due
to hereditary AAT deficiency, to be administered by inhalation.PRX-107 is a
protein that works by regulating the AAT-dependent inflammatory response in
the lungs.Currently, there is no approved recombinant form of AAT.Plasma
derived-forms of AAT are available, but are associated with limitations,
including inadequate supply, the potential for adventitious agents and poor
absorption. In preclinical studies, PRX-107 demonstrated the ability to rescue
elastase induced lung damage in rats and as effective as a plasma-derived
reagent. The Company plans to hold a pre-IND meeting with the FDA in the
second half of 2013 to discuss next steps for this compound.

Additional information on these compounds can be found in the slides presented
at the Company's Analyst Day on June 20, 2013.These are available under the
presentation tab on the Company's website.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins expressed through its
proprietary plant cell based expression system, ProCellEx®.Protalix's unique
expression system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner.Protalix's first
product manufactured by ProCellEx, taliglucerase alfa, was approved for
marketing by the U.S. Food and Drug Administration (FDA) in May 2012, by
Israel's Ministry of Health in September 2012, by the Brazilian National
Health Surveillance Agency (ANVISA) in March 2013, by the Mexican Federal
Commission for the Protection against Sanitary Risk (COFEPRIS) in April 2013,
and by the regulatory authorities of other countries.Marketing applications
for taliglucerase alfa have been filed in additional territories as
well.Protalix has partnered with Pfizer Inc. for the worldwide development
and commercialization of taliglucerase alfa, excluding Israel and Brazil,
where Protalix retains full rights.Protalix's development pipeline also
includes the following product candidates: PRX-102, a modified version of the
recombinant human alpha-GAL-A protein for the treatment of Fabry disease;
PRX-105, a pegylated recombinant human acetylcholinesterase in development for
several therapeutic and prophylactic indications, a biodefense program and an
organophosphate-based pesticide treatment program; an orally-delivered
glucocerebrosidase enzyme that is produced and encapsulated within carrot
cells, also for the treatment of Gaucher disease; pr-antiTNF, a similar plant
cell version of etanercept (Enbrel®) for the treatment of certain immune
diseases such as rheumatoid arthritis, juvenile idiopathic arthritis,
ankylosing spondylitis, psoriatic arthritis and plaque psoriasis; PRX-110 for
the treatment of Cystic Fibrosis; PRX-107 for the treatment of emphysema due
to hereditary alpha1-antitrypsin deficiency; and others.

Forward Looking Statements

To the extent that statements in this press release are not strictly
historical, all such statements are forward-looking, and are made pursuant to
the safe-harbor provisions of the Private Securities Litigation Reform Act of
1995.The terms "anticipate," "believe," "estimate," "expect," "plan" and
"intend" and other words or phrases of similar import are intended to identify
forward-looking statements.These forward-looking statements are subject to
known and unknown risks and uncertainties that may cause actual future
experience and results to differ materially from the statements made.These
statements are based on our current beliefs and expectations as to such future
outcomes.Drug discovery and development involve a high degree of
risk.Factors that might cause material differences include, among others:
failure or delay in the commencement or completion of our preclinical studies
and clinical trials which may be caused by several factors, including:
unforeseen safety issues; determination of dosing issues; lack of
effectiveness during clinical trials; slower than expected rates of patient
recruitment; inability to monitor patients adequately during or after
treatment; inability or unwillingness of medical investigators and
institutional review boards to follow our clinical protocols; and lack of
sufficient funding to finance the clinical trials; the risk that the results
of our clinical trials will not support the applicable claims of safety or
efficacy, that our product candidates will not have the desired effects or
includes undesirable side effects or other unexpected characteristics; our
dependence on performance by third party providers of services and supplies,
including without limitation, clinical trial services; delays in our
preparation and filing of applications for regulatory approval; delays in the
approval or potential rejection of any applications we file with the FDA, or
other health regulatory authorities; the inherent risks and uncertainties in
developing drug platforms and products of the type we are developing; the
impact of development of competing therapies and/or technologies by other
companies and institutions; potential product liability risks; risks related
to the potential infringement of a third party's patents or other intellectual
property rights;the uncertainty of obtaining patents covering our products
and processes and in successfully enforcing our intellectual property rights
against third parties; risks of securing adequate levels of product liability
and clinical trial insurance coverage; and other factors described in our
filings with the U.S. Securities and Exchange Commission.The statements in
this release are valid only as of the date hereof and we disclaim any
obligation to update this information.

CONTACT: Investor Contact
        
         Marcy Nanus
         The Trout Group, LLC
         646-378-2927
         mnanus@troutgroup.com
        
         Media Contact
        
         Kari Watson
         MacDougall Biomedical Communications
         781-235-3060
         kwatson@macbiocom.com
 
Press spacebar to pause and continue. Press esc to stop.